首页|Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease:Current Progress and Challenges

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease:Current Progress and Challenges

扫码查看
原文链接
  • 万方数据
  • 维普
The prevalence of metabolic-dysfunction-associated steatotic liver disease(MASLD)is alarmingly high;it is estimated to affect up to a quarter of the global population,making it the most common liver disorder worldwide.MASLD is characterized by excessive hepatic fat accumulation and is commonly associated with comorbidities such as obesity,dyslipidemia,and insulin resistance;however,it can also manifest in lean individuals.Therefore,it is crucial to develop effective therapies for this complex condition.Currently,there are no approved medications for MASLD treatment,so there is a pressing need to inves-tigate alternative approaches.Extensive research has characterized MASLD as a multifaceted disease,fre-quently linked to metabolic disorders that stem from dietary habits.Evidence suggests that changes in the gut microbiome play a fundamental role in the development and progression of MASLD from simple steatosis to steatohepatitis and even hepatocellular carcinoma(HCC).In this review,we critically examine the literature on the emerging field of gut-microbiota-based therapies for MASLD and metabolic-dysfunction-associated steatohepatitis(MASH),including interventions such as fecal microbiota transplantation(FMT),probiotics,prebiotics,short-chain fatty acids,antibiotics,metabolic pathway targeting,and immune checkpoint kinase blockade.

MicrobiomeFecal microbiota transplantationMetabolic-dysfunction-associated steatoticliver diseaseFatty liver

Ernesto Saenz、Nathally Espinosa Montagut、Baohong Wang、Christoph Stein-Thöringer、Kaicen Wang、Honglei Weng、Matthias Ebert、Kai Markus Schneider、Lanjuan Li、Andreas Teufel

展开 >

Division of Hepatology,Division of Clinical Bioinformatics,Department of Medicine Ⅱ,Medical Faculty Mannheim,Heidelberg University,Mannheim 68167,Germany

Clinical Cooperation Unit Healthy Metabolism,Center for Preventive Medicine and Digital Health,Medical Faculty Mannheim,Heidelberg University,Mannheim 68167,Germany

School of Medicine,Universidad de Los Andes,Bogota 111711,Colombia

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China

Internal Medicine Ⅰ,University Clinic Tuebingen & CoE CMFI(Controlling Microbes to Fight Infections),Tuebingen 72074,Germany

Department of Medicine Ⅱ,Medical Faculty Mannheim,Heidelberg University,Mannheim 68167,Germany

DKFZ Hector Cancer Institute at the University Medical Center,Mannheim 69120,Germany

Molecular Medicine Partnership Unit,European Molecular Biology Laboratory,Heidelberg 69117,Germany

Department of Medicine Ⅲ,University Hospital RWTH Aachen,Aachen 52074,Germany

展开 >

Andreas Teufel received grants from the Federal Ministry of Education and ResearchAndreas Teufel received grants from the Federal Ministry of Education and ResearchSino-German Center for Research PromotionSino-German Center for Research PromotionState Ministry of Baden-Wuerttemberg for Sciences,Research and Arts supporting the Clinical Cooperation Unit Healthy MetabolBaden-Wuerttemberg Center for Digital Early Disease Detection and Prevention(BW-ZDFP)Foundation for Biomedical Alcohol Research,Schriesheim,GermanyFederal Ministry of Education and Research(BMBF)Ministry of Culture and Science of the German State of North Rhine-Westphalia(MKW)(NRW Rueckkehrprogramm)under the ExcellencL?nderGerman Research FoundationGerman Research FoundationGerman Research Foundation

Q-HCC01KD2214GZ-1546C-0012DFG403224013-SFB1382gutliver axis

2024

10.1016/j.eng.2024.03.019

工程(英文)

工程(英文)

CSTPCDEI
ISSN：2095-8099
年,卷(期)：2024.40(9)